ストックスクリーナーアプリを入手
6.50
0.38%
-0.025
前日終値:
$6.525
開ける：
$6.52
24時間の取引高:
944.25K
Relative Volume:
0.53
時価総額：
$618.77M
収益：
-
当期純損益:
$-29.07M
株価収益率:
-22.41
EPS:
-0.29
ネットキャッシュフロー:
$-31.85M
1週間 パフォーマンス:
+0.46%
1か月 パフォーマンス:
+44.44%
6か月 パフォーマンス:
+95.20%
1年 パフォーマンス:
+88.41%
1日の値動き範囲:
$6.36
$6.68
1週間の範囲:
$6.22
$6.785
52週間の値動き範囲:
$2.30
$7.39
Trevi Therapeutics Inc Stock (TRVI) Company Profile
名前
Trevi Therapeutics Inc
セクター
電話
203-304-2499
住所
195 CHURCH STREET, NEW HAVEN, CT
TRVI を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
6.50 | 618.77M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
492.69 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
637.36 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
589.15 | 35.93B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
268.46 | 34.75B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
267.39 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-10 | 繰り返されました | Needham | Buy |
| 2025-03-10 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-09 | 再開されました | Leerink Partners | Outperform |
| 2024-08-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-30 | 開始されました | Raymond James | Outperform |
| 2024-06-13 | 開始されました | Rodman & Renshaw | Buy |
| 2023-04-12 | 開始されました | B. Riley Securities | Buy |
| 2022-11-22 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | BMO Capital Markets | Outperform |
| 2019-06-03 | 開始されました | Needham | Buy |
| 2019-06-03 | 開始されました | SVB Leerink | Outperform |
| 2019-06-03 | 開始されました | Stifel | Buy |
すべてを表示
Trevi Therapeutics Inc (TRVI) 最新ニュース
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Acquired by Bank of New York Mellon Corp - Defense World
Trevi therapeutics chief scientific officer Sciascia sells $17,364 in stock - Investing.com
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock By Investing.com - Investing.com South Africa
Trevi therapeutics CEO Jennifer Good sells $34,624 in stock - Investing.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q4 2024 Earnings Call Transcript - Insider Monkey
Q3 EPS Estimate for Trevi Therapeutics Reduced by Analyst - Defense World
Equities Analysts Offer Predictions for TRVI Q2 Earnings - Defense World
Leerink Partnrs Analysts Boost Earnings Estimates for TRVI - Defense World
HC Wainwright Reiterates “Buy” Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Earns “Buy” Rating from B. Riley - Defense World
D. Boral Capital Reaffirms Buy Rating for Trevi Therapeutics (NASDAQ:TRVI) - Defense World
Needham & Company LLC Lowers Trevi Therapeutics (NASDAQ:TRVI) Price Target to $24.00 - Defense World
Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Price Target at $15.94 - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Shares Gap Up Following Better-Than-Expected Earnings - Defense World
Trevi Therapeutics Stock (TRVI) Surges Over 60% on Promising Trial Results and Q4 Financials - Markets Insider
B. Riley Boosts Price Target on Trevi Therapeutics to $20 From $11, Keeps Buy Rating - Marketscreener.com
Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing ... - Yahoo Finance
Trevi Therapeutics Inc (TRVI) Q4 2024 Earnings Call Highlights: Navigating Losses and Advancing Promising Trials - GuruFocus.com
Trevi Therapeutics Advances Haduvio in Clinical Trials - TipRanks
Earnings call transcript: Trevi Therapeutics Q4 2024 reports mixed results - Investing.com
Trevi Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Trevi Therapeutics Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Updates - PR Newswire
TRVI Stock Soars on Meeting Primary Goal in Chronic Cough Study - MSN
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) large institutional owners must be happy as stock continues to impress, up 57% over the past week - Yahoo Finance
Trevi Therapeutics Inc expected to post a loss of 12 cents a shareEarnings Preview - TradingView
HC Wainwright Analysts Increase Earnings Estimates for TRVI - Defense World
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock By Investing.com - Investing.com Australia
Trevi Therapeutics’ chief commercial officer sells $548,877 in stock - Investing.com India
Biotech Alert: Searches spiking for these stocks today - TipRanks
Investors Buy High Volume of Trevi Therapeutics Call Options (NASDAQ:TRVI) - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Price Target Raised to $20.00 at Oppenheimer - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Hits New 52-Week High After Analyst Upgrade - Defense World
Trevi Therapeutics (TRVI) Projected to Post Quarterly Earnings on Wednesday - Defense World
Trevi Therapeutics to Report Fourth Quarter and Year End 2024 Financial Results and Provide a Corporate Update on March 18, 2025 - The Malaysian Reserve
Trevi Therapeutics price target raised to $20 from $12 at Oppenheimer - TipRanks
Trevi Therapeutics (NASDAQ:TRVI) Receives Buy Rating from D. Boral Capital - MarketBeat
Trevi Therapeutics (NASDAQ:TRVI) Given New $12.50 Price Target at HC Wainwright - Defense World
Trevi Therapeutics (NASDAQ:TRVI) Upgraded to Strong-Buy at Raymond James - Defense World
Needham & Company LLC Issues Positive Forecast for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - Defense World
Trevi Therapeutics to Participate in Upcoming March Investor Conferences - Kilgore News Herald
Trevi Therapeutics stock soars to 52-week high of $6.58 By Investing.com - Investing.com Australia
Trevi Therapeutics reports positive Phase 2a trial results - Investing.com India
Trevi Therapeutics reports positive Phase 2a trial results By Investing.com - Investing.com South Africa
Trevi Therapeutics Just Got a 212% Price Target Bump – Here’s Why - Wall Street Pit
Cough in Idiopathic Pulmonary Fibrosis Pipeline 2024: MOA, ROA, - openPR
Trevi Gets A Clap On The Back For Chronic Cough Data - Citeline News & Insights
Trevi Therapeutics Reveals Positive Data From Mid-Stage Study For Chronic Cough Candidate, Stock Jumps - AOL
Leerink raises Trevi Therapeutics stock target to $11 - Investing.com
Leerink raises Trevi Therapeutics stock target to $11 By Investing.com - Investing.com Canada
HC Wainwright Adjusts Trevi Therapeutics Price Target to $12.50 From $7.50, Maintains Buy Rating - Marketscreener.com
Trevi Therapeutics stock soars to 52-week high of $6.58 - Investing.com
Trevi Therapeutics Inc (TRVI) 財務データ
収益
当期純利益
現金流量
EPS
Trevi Therapeutics Inc (TRVI) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| SCIASCIA THOMAS | Chief Scientific Officer |
Mar 25 '25 |
Sale |
6.60 |
2,631 |
17,365 |
221,373 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Option Exercise |
1.43 |
5,263 |
7,526 |
218,576 |
| GOOD JENNIFER L | President & CEO |
Mar 21 '25 |
Sale |
6.58 |
5,263 |
34,625 |
213,313 |
0.39%
0.34%
大文字化:
|
ボリューム (24 時間):